Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 19/74 ]
NYSE | Common Stock
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally.
It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints.
In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions.
Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems.
The company serves the healthcare providers.
Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 1, 24 | 0.00 Decreased by N/A% | - |
| Feb 27, 24 | 0.00 Decreased by -100.00% | 0.96 Decreased by -100.00% |
| Nov 2, 23 | 0.00 Decreased by N/A% | - |
| Aug 3, 23 | 0.35 Increased by +75.00% | 0.81 Decreased by -56.79% |
| Apr 26, 23 | 0.00 Decreased by N/A% | - |
| Feb 21, 23 | 0.05 Decreased by -86.11% | 0.85 Decreased by -94.12% |
| Nov 3, 22 | 0.00 Decreased by N/A% | - |
| Jul 28, 22 | 0.20 Decreased by -74.36% | 0.80 Decreased by -75.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 2.83 B Increased by +3.06% | 214.00 M Increased by +343.51% | Increased by +7.57% Increased by +330.33% |
| Dec 31, 23 | 2.79 B Increased by +113.59% | 90.28 M Increased by +292.51% | Increased by +3.23% Increased by +83.77% |
| Jun 30, 23 | 2.73 B Increased by +5.15% | 172.00 M Decreased by -2.82% | Increased by +6.29% Decreased by -7.59% |
| Mar 31, 23 | 1.37 B Increased by +5.15% | 86.00 M Decreased by -2.82% | Increased by +6.29% Decreased by -7.59% |
| Dec 31, 22 | 2.74 B Increased by +4.01% | 48.25 M Decreased by -85.01% | Increased by +1.76% Decreased by -85.59% |
| Sep 30, 22 | 1.31 B Increased by +0.08% | 23.00 M Decreased by -85.58% | Increased by +1.76% Decreased by -85.59% |
| Jun 30, 22 | 2.60 B Increased by +0.04% | 177.00 M Decreased by -13.66% | Increased by +6.81% Decreased by -13.69% |
| Mar 31, 22 | 1.30 B Increased by +0.04% | 88.50 M Decreased by -13.66% | Increased by +6.81% Decreased by -13.69% |